Bin Chang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Bin Chang has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
Chika Takano
Departiment of Pediatrics and Child Health, Nihon University School of Medicine
1 shared publication- Dong Wook Kim
Department of Pharmacy, College of Pharmacy, Hanyang University
1 shared publication Eun Jin Kim
Department of Pharmacy, College of Pharmacy, Hanyang University
1 shared publicationHiroko Oguchi
Division of Pediatric Dentistry, Department of Human Development and Fostering, Meikai University School of Dentistry
1 shared publicationHiroshi Mukae
Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan
1 shared publicationJun Sakai
Department of Infectious Disease and Infection Control, Saitama Medical University
1 shared publication
Latest Publications
- Open Access
- 27 October 2026
- Published by American Society for Microbiology in Microbiology Spectrum
Enhanced LAMP-based assay for rapid detection of non-vaccine Streptococcus pneumoniae capsular types in meningitis
Streptococcus pneumoniae remains a major pathogen responsible for invasive pneumococcal diseases (IPDs), such as meningitis and bacteremia, particularly affecting children under five and older adults. The introduction of pneumococcal conjugate vaccines (PCVs) has led to significant reductions in IPD incidence, yet the challenge of capsular-type replacement persists. Conventional serological typing methods, such as the Quellung reaction, are limited by their requirement for technical expertise and specialized resources, especially in low- and middle-income countries. To address these challenges, we previously developed loop-mediated isothermal amplification (LAMP)-based capsular typing assays for PCV13 and PPSV23. This study aimed to develop improved LAMP assays targeting fifteen non-vaccine capsular types (6C, 7C, 13, 15A, 16F, 21, 23A, 23B, 24F, 31, 34, 35B, 35F, 38, 39), and to assess their suitability for detecting these capsular types in cerebrospinal fluid (CSF) and blood. Each assay was evaluated to determine analytical reactivity, analytical specificity, and analytical sensitivity, and its performance was compared with that of CDC conventional multiplex PCR. To assess their applicability in patients with suspected meningitis, analytical detection limits were determined using bacterial genomic DNA-spiked CSF and blood specimens. The analytical specificity of the LAMP assays was confirmed using 50 capsular types of pneumococcal strains. The assays detected as few as 100 copies of purified DNA as well as DNA spiked into CSF and blood, demonstrating greater analytical sensitivity than conventional PCR. This highly specific, sensitive, and robust LAMP assay provides substantial advantages for large-scale screening, particularly in resource-limited settings. IMPORTANCE: This is the first report of LAMP assays for these 15 capsular types of S. pneumoniae . LAMP assays demonstrated 10–1,000-fold improved analytical sensitivity over conventional PCR for several capsular types. Established LAMP assays targeting non-vaccine pneumococcal capsular types offer substantial value for public-health surveillance of IPDs. Monitoring these capsular types is particularly important for assessing the impact of newly introduced vaccines, such as PCV20 and PCV21. This approach enables efficient IPD surveillance even in resource-limited settings, supports timely optimization of vaccination strategies, and contributes to reducing the global IPD burden. This method may serve as a pivotal tool for tracking vaccine impacts in regions where non-vaccine-targeted capsular types represent an emerging threat.
- 27 October 2026
- Published by American Society for Microbiology in Microbiology Spectrum
Open AccessEnhanced LAMP-based assay for rapid detection of non-vaccine Streptococcus pneumoniae capsular types in meningitis
Streptococcus pneumoniae remains a major pathogen responsible for invasive pneumococcal diseases (IPDs), such as meningitis and bacteremia, particularly affecting children under five and older adults. The introduction of pneumococcal conjugate vaccines (PCVs) has led to significant reductions in IPD incidence, yet the challenge of capsular-type replacement persists. Conventional serological typing methods, such as the Quellung reaction, are limited by their requirement for technical expertise and specialized resources, especially in low- and middle-income countries. To address these challenges, we previously developed loop-mediated isothermal amplification (LAMP)-based capsular typing assays for PCV13 and PPSV23. This study aimed to develop improved LAMP assays targeting fifteen non-vaccine capsular types (6C, 7C, 13, 15A, 16F, 21, 23A, 23B, 24F, 31, 34, 35B, 35F, 38, 39), and to assess their suitability for detecting these capsular types in cerebrospinal fluid (CSF) and blood. Each assay was evaluated to determine analytical reactivity, analytical specificity, and analytical sensitivity, and its performance was compared with that of CDC conventional multiplex PCR. To assess their applicability in patients with suspected meningitis, analytical detection limits were determined using bacterial genomic DNA-spiked CSF and blood specimens. The analytical specificity of the LAMP assays was confirmed using 50 capsular types of pneumococcal strains. The assays detected as few as 100 copies of purified DNA as well as DNA spiked into CSF and blood, demonstrating greater analytical sensitivity than conventional PCR. This highly specific, sensitive, and robust LAMP assay provides substantial advantages for large-scale screening, particularly in resource-limited settings. IMPORTANCE: This is the first report of LAMP assays for these 15 capsular types of S. pneumoniae . LAMP assays demonstrated 10–1,000-fold improved analytical sensitivity over conventional PCR for several capsular types. Established LAMP assays targeting non-vaccine pneumococcal capsular types offer substantial value for public-health surveillance of IPDs. Monitoring these capsular types is particularly important for assessing the impact of newly introduced vaccines, such as PCV20 and PCV21. This approach enables efficient IPD surveillance even in resource-limited settings, supports timely optimization of vaccination strategies, and contributes to reducing the global IPD burden. This method may serve as a pivotal tool for tracking vaccine impacts in regions where non-vaccine-targeted capsular types represent an emerging threat.
- Open Access
- 31 July 2026
- Published by Microbiology Society in Microbial Genomics
- Vol. 12 (7) , 001808
Phylogenetic analysis of serotype 19A-sequence type (ST)2331 Streptococcus pneumoniae associated with the Pneumococcal Molecular Epidemiology Network (PMEN)34 clone predominant in Japan after the introduction of the 7-valent pneumococcal conjugate vaccine (PCV7)
Following the introduction of the 7-valent pneumococcal conjugate vaccine (PCV7), serotype 19A Streptococcus pneumoniae emerged as a major cause of paediatric pneumococcal disease in Japan. Unlike global trends, in which multidrug-resistant serotype 19A-sequence type (ST)320 predominated, serotype 19A-ST2331 became one of the dominant lineages in Japan. The evolutionary origins of serotype 19A-ST2331 and the reasons for its domestic success remain unclear. To investigate the evolutionary origin and dissemination of the serotype 19A-ST2331 lineage, we analysed whole-genome sequences of 42 clonal complex (CC)2331 isolates collected in Japan between 2004 and 2017 and compared them with 825 genetically related global isolates. Phylogenetic analysis showed that Japanese serotype 19A-ST2331 isolates formed a distinct Japan-associated cluster within Global Pneumococcal Sequence Cluster 32 that was closely related to the globally disseminated Pneumococcal Molecular Epidemiology Network (PMEN)34 clone, typically represented by serotype 12F-ST218. Among the 42 Japanese CC2331 isolates, 40 were serotype 19A, whereas only two non-19A isolates were identified. Serotype 19A was absent from the 825 non-Japanese isolates, indicating that serotype 19A-ST2331 represents a globally rare, Japan-specific lineage. Most Japanese isolates remained susceptible to β-lactams, whereas 83.3% were erythromycin-resistant and carried either mefA/E or ermB . A highly clonal mefA/E -positive subclade was dated to a most recent common ancestor at ∼1998.5. These findings indicate that serotype 19A-ST2331 emerged before 2000 from an ST218-related ancestor through serotype switching and subsequently underwent local expansion in Japan. Although the ancestral intermediate was not represented in the present collection, the successful establishment of this clone may have been facilitated by the combined selective advantages conferred by the serotype 19A capsule and macrolide resistance in the post-PCV7 setting in Japan.
- 31 July 2026
- Published by Microbiology Society in Microbial Genomics
- Vol. 12 (7) , 001808
Open AccessPhylogenetic analysis of serotype 19A-sequence type (ST)2331 Streptococcus pneumoniae associated with the Pneumococcal Molecular Epidemiology Network (PMEN)34 clone predominant in Japan after the introduction of the 7-valent pneumococcal conjugate vaccine (PCV7)
Following the introduction of the 7-valent pneumococcal conjugate vaccine (PCV7), serotype 19A Streptococcus pneumoniae emerged as a major cause of paediatric pneumococcal disease in Japan. Unlike global trends, in which multidrug-resistant serotype 19A-sequence type (ST)320 predominated, serotype 19A-ST2331 became one of the dominant lineages in Japan. The evolutionary origins of serotype 19A-ST2331 and the reasons for its domestic success remain unclear. To investigate the evolutionary origin and dissemination of the serotype 19A-ST2331 lineage, we analysed whole-genome sequences of 42 clonal complex (CC)2331 isolates collected in Japan between 2004 and 2017 and compared them with 825 genetically related global isolates. Phylogenetic analysis showed that Japanese serotype 19A-ST2331 isolates formed a distinct Japan-associated cluster within Global Pneumococcal Sequence Cluster 32 that was closely related to the globally disseminated Pneumococcal Molecular Epidemiology Network (PMEN)34 clone, typically represented by serotype 12F-ST218. Among the 42 Japanese CC2331 isolates, 40 were serotype 19A, whereas only two non-19A isolates were identified. Serotype 19A was absent from the 825 non-Japanese isolates, indicating that serotype 19A-ST2331 represents a globally rare, Japan-specific lineage. Most Japanese isolates remained susceptible to β-lactams, whereas 83.3% were erythromycin-resistant and carried either mefA/E or ermB . A highly clonal mefA/E -positive subclade was dated to a most recent common ancestor at ∼1998.5. These findings indicate that serotype 19A-ST2331 emerged before 2000 from an ST218-related ancestor through serotype switching and subsequently underwent local expansion in Japan. Although the ancestral intermediate was not represented in the present collection, the successful establishment of this clone may have been facilitated by the combined selective advantages conferred by the serotype 19A capsule and macrolide resistance in the post-PCV7 setting in Japan.
- Open Access
- 8 January 2024
- Published by Microbiology Society in Journal of Medical Microbiology
- Vol. 73 (1) , 001784
Clinical features relating to pneumococcal colony phase variation in hospitalized adults with pneumonia
Background. Streptococcus pneumoniae is a major causative bacteria of pneumonia and invasive pneumococcal disease (IPD); however, the mechanisms underlying its severity and invasion remain to be defined. Pneumococcal colonies exhibit opaque and transparent opacity phase variations, which have been associated with invasive infections and nasal colonization, respectively, in animal studies. This study evaluated the relationship between the opacity of pneumococcal colonies and the clinical presentation of pneumococcal pneumonia. Methods. This retrospective study included adult patients hospitalized with pneumococcal pneumonia between 2012 and 2019 at four tertiary medical institutions. Pneumococcal strains from lower respiratory tract specimens were determined for their serotypes and microscopic colony opacity, and the association between the opacity phase and the severity of pneumonia was evaluated. Serotypes 3 and 37 with mucoid colony phenotypes were excluded from the study because their colony morphologies were clearly different. Results. A total of 92 patients were included. Most patients were older adults (median age: 72 years) and males (67 %), and 59 % had community-acquired pneumonia. Of the 92 patients, 41 (45 %), 12 (13 %), and 39 (42 %) patients had opaque, transparent, and mixed variants in their pneumococcal colony, respectively. The opaque and non-opaque pneumococcal variants had no statistically significant difference in patient backgrounds. Although the pneumonia severity index score did not differ between the opaque and non-opaque groups, the rate of bacteremia was significantly higher in the opaque group than in the non-opaque group. Serotype distribution was similar between the groups. Conclusions. Opaque pneumococcal variants may cause pneumonia and invasive diseases in humans. This study could help elucidate IPD, and opacity assessment may serve as a predictor for IPD.
- 8 January 2024
- Published by Microbiology Society in Journal of Medical Microbiology
- Vol. 73 (1) , 001784
Open AccessClinical features relating to pneumococcal colony phase variation in hospitalized adults with pneumonia
Background. Streptococcus pneumoniae is a major causative bacteria of pneumonia and invasive pneumococcal disease (IPD); however, the mechanisms underlying its severity and invasion remain to be defined. Pneumococcal colonies exhibit opaque and transparent opacity phase variations, which have been associated with invasive infections and nasal colonization, respectively, in animal studies. This study evaluated the relationship between the opacity of pneumococcal colonies and the clinical presentation of pneumococcal pneumonia. Methods. This retrospective study included adult patients hospitalized with pneumococcal pneumonia between 2012 and 2019 at four tertiary medical institutions. Pneumococcal strains from lower respiratory tract specimens were determined for their serotypes and microscopic colony opacity, and the association between the opacity phase and the severity of pneumonia was evaluated. Serotypes 3 and 37 with mucoid colony phenotypes were excluded from the study because their colony morphologies were clearly different. Results. A total of 92 patients were included. Most patients were older adults (median age: 72 years) and males (67 %), and 59 % had community-acquired pneumonia. Of the 92 patients, 41 (45 %), 12 (13 %), and 39 (42 %) patients had opaque, transparent, and mixed variants in their pneumococcal colony, respectively. The opaque and non-opaque pneumococcal variants had no statistically significant difference in patient backgrounds. Although the pneumonia severity index score did not differ between the opaque and non-opaque groups, the rate of bacteremia was significantly higher in the opaque group than in the non-opaque group. Serotype distribution was similar between the groups. Conclusions. Opaque pneumococcal variants may cause pneumonia and invasive diseases in humans. This study could help elucidate IPD, and opacity assessment may serve as a predictor for IPD.